The cheeks may look flatter
Indiana University researcher Richard DiMarchi played a crucial role in the development of GLP-1 drugs for obesity treatment
This means your body handles coffee and your GLP-1 injection as independent substances, each following its own path through digestion and elimination
Phase 2 obesity trial (NEJM 2023) adverse events by maintenance dose (where a dose had two escalation arms, the range across both arms is shown): Phase 2 type 2 diabetes trial (Lancet 2023): mild-to-moderate gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) were reported in 35% of retatrutide participants ranging from 13% at 0.5 mg to 50% in the 8 mg fast-escalation group compared with 13% on placebo and 35% on dulaglutide 1.5 mg
Rubbing the injection site is not recommended
If you have diabetes and are unsure about your eligibility or safety, consulting an experienced diabetes specialist , such as Dr Moxit Shah before donating blood is the best way to ensure both your well-being and the safety of the recipient